RxDoctor Payments Data

Amy Magnuson, MD

Family Medicine · Vista, CANPI 1558521583

Payments from drug & device makers

$1,906in general payments, 2019–2025

Across 37 payments — averaging $51.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cue Health Inc.$867
  • Lilly USA, LLC$420
  • Novo Nordisk$333
  • Pfizer$132
  • Abbott$28
  • Johnson & Johnson$27
  • plus $100 from 5 others

What the payments were for

  • Food & beverage$1,02854%
  • Education$121%
  • Gifts$86745%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Cue Health Inc.1$867
Lilly USA, LLC9$420
Novo Nordisk12$333
Pfizer7$132
Abbott1$28
Johnson & Johnson2$27
Linus Health, Inc.1$26
Nevro Corp.1$20
Aytu Biopharma, Inc.1$20
GSK1$19
Cranial Technologies, Inc1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,906 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$27,951
Medicare patients
99
Services billed
716

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide16$27,951
MounjaroTirzepatide12$16,111
Breo ElliptaFluticasone/Vilanterol24$11,006
Bupropion XlBupropion Hcl39$2,449
Atorvastatin Calcium176$1,998
Celecoxib23$1,982
Estradiol21$1,754
Famotidine15$1,020
Potassium Chloride25$817
Levothyroxine Sodium72$745
Amlodipine Besylate77$709
Gabapentin41$706
Albuterol Sulfate HfaAlbuterol Sulfate22$705
Omeprazole47$554
Losartan Potassium39$500

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$333$27,95116 claims
Lilly USA, LLCMounjaro$420$16,11112 claims
GSKBreo Ellipta$19$11,00624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Vista

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →